Generic QOL | Fatigue | Lung | Skin | Eye | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SF36 | FAS | FVC | SGRQ | MRC | DLQI | PGA | VFQ-25 | VA | |||||
PCS | MCS | Total | % Pred | Sym | Act | Imp | Tot | Breathlessness | Total | Total | |||
KSQ modules | |||||||||||||
General health status | 0.64 | 0.70 | −0.86 | – | −0.49 | −0.67 | −0.66 | −0.70 | −0.57 | −0.35 | – | 0.66 | – |
Lung | 0.71 | 0.39 | −0.60 | 0.47 | −0.74 | −0.78 | −0.78 | −0.85 | −0.58 | – | – | – | – |
Skin | 0.32* | 0.47** | −0.42** | – | – | – | – | – | – | −0.67 | −0.53 | – | – |
Eye | 0.56** | 0.55** | −0.59 | – | – | – | – | – | – | – | – | 0.80 | −0.56** |
Medication | 0.25* | 0.29** | −0.35 | – | −0.31** | −0.33 | −0.41 | −0.40 | −0.29 | −0.38 | – | 0.27* | – |
Overall Health Status | |||||||||||||
Lung+GHS | 0.73 | 0.62 | −0.82 | 0.49 | −0.66 | −0.78 | −0.77 | −0.83 | −0.62 | – | – | – | – |
Skin+GHS | 0.58 | 0.69 | −0.78 | – | – | – | – | – | – | −0.48** | −0.38* | – | – |
Eye+GHS | 0.60 | 0.66 | −0.82 | – | – | – | – | – | – | – | – | 0.80 | −0.45** |
Lung+Skin+GHS | 0.70 | 0.63 | −0.79 | 0.45 | −0.65 | −0.79 | −0.76 | −0.83 | −0.64 | −0.47** | −0.38* | – | – |
Data shown are Pearson's correlation coefficients for organ-specific comparisons. All p<0.001 (stronger evidence of association) except **p<0.01 and ≥0.001 (some evidence of association) and *p<0.05 and >0.01 (possibly due to chance or only suggestive of association).
Act, activity; DLQI, Dermatology Life Quality Index; FAS, Fatigue Assessment Scale; FVC, forced vital capacity; HS, health status; Imp, impact; KSQ, King's Sarcoidosis Questionnaire; MRC, Medical Research Council dyspnoea scale; PGA, Physicians Global Assessment; SGRQ, St George's Respiratory Questionnaire—Symptoms; Sym, symptoms; Tot, total; SF-36 PCS, Short Form 36 Physical Component Summary; SF-36 MCS, Short Form 36 Mental Component Summary; VA, visual acuity; VFQ-25, Visual Function Questionnaire (25 items); –, not applicable.